Lawmakers in the US House of Representatives have ditched a widely-supported amendment that would have changed the rules on advertising pharmaceutical products, requiring drugmakers to list prices in TV adverts.
At the time of its introduction last year, the American Medical Association (AMA) welcomed the legislation, saying it would help bring “much-needed transparency to drug pricing and provide a clear benefit to consumers struggling with exorbitant costs.”
The amendment was said to have been favored by both Democrats and Republicans, and patient groups, leading some to point the blame for its failure at pharmaceutical lobbyists.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze